Shanghai Henlius Biotech, Inc.
2696
Xếp hạng trong cổ phiếu
#4247
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Giá cổ phiếu
$6.84
Đồng bộ lần cuối: 2026-10-21
Vốn hóa thị trường
$3.73B
Thay đổi (1 ngày)
2.29%
Thay đổi (1 năm)
-25.41%
Quốc gia
CN
Giao dịch Shanghai Henlius Biotech, Inc. (2696)
Danh mục
Healthcare
Doanh thu của Shanghai Henlius Biotech, Inc. (2696)
Doanh thu vào Jun 2026 TTM: $1.08B
Theo các báo cáo tài chính gần đây của Shanghai Henlius Biotech, Inc., doanh thu hiện tại của công ty (TTM) là $1.08B. Trong năm 2023, công ty đạt doanh thu $762.14M tăng so với doanh thu năm 2022, là $466.04M. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Shanghai Henlius Biotech, Inc. từ 2017 đến 2026
Doanh thu vào cuối mỗi năm
| Năm | Doanh thu | Thay đổi |
|---|---|---|
| 2026 (TTM) | $1.08B | 37.39% |
| 2024 | $784.27M | 2.90% |
| 2023 | $762.14M | 63.53% |
| 2022 | $466.04M | 76.06% |
| 2021 | $264.71M | 194.30% |
| 2020 | $89.95M | 588.80% |
| 2019 | $13.06M | 1,110.39% |
| 2018 | $1.08M | -79.30% |
| 2017 | $5.21M | 0.00% |
Doanh thu của các công ty hoặc đối thủ tương tự
| Công ty | Doanh thu | Chênh lệch doanh thu | Quốc gia |
|---|---|---|---|
| $12.62B | 1,071.65% |
US
|
|
| $2.23B | 106.78% |
US
|
|
| $15.74B | 1,361.22% |
AU
|
|
| $6.02B | 458.83% |
NL
|
|
| - | - |
CH
|
